1. Signaling Pathways
  2. Cell Cycle/DNA Damage
    Epigenetics
  3. Sirtuin
  4. SIRT4 Isoform

SIRT4

SIRT4

SIRT4 is a mitochondrial member of the sirtuin family that functions as an NAD+-dependent metabolic regulator and is distinguished by its prominent ADP-ribosyltransferase activity toward glutamate dehydrogenase (GDH)[1][2]. Mechanistically, SIRT4 represses mitochondrial glutamine and glutamate metabolism through ADP-ribosylation-mediated inhibition of GDH, thereby reducing amino acid-stimulated insulin secretion and modulating cellular energy homeostasis[1][2][3]. Beyond GDH regulation, SIRT4 participates in broader metabolic control, including the regulation of fatty acid oxidation, branched-chain amino acid catabolism, and mitochondrial metabolic adaptation during nutrient stress[4][5][6]. These functions position SIRT4 as an important regulator of mitochondrial metabolism and endocrine signaling in pancreatic β cells and other metabolically active tissues[1][4]. In disease contexts, reduced SIRT4 activity or expression has been associated with enhanced glutamine utilization and tumor progression, whereas restoration of SIRT4 suppresses proliferation and promotes tumor-suppressive metabolic programs in multiple experimental cancer models[7][8][9]. Compared with related mitochondrial isoforms such as SIRT3 and SIRT5, which primarily function through deacylation-dependent activation or remodeling of metabolic enzymes, SIRT4 is notable for suppressing metabolic flux through ADP-ribosylation-mediated inhibition of key mitochondrial targets[1][10]. For experimental applications, selective SIRT4 inhibitors have recently been reported, providing emerging tools for mechanistic studies of mitochondrial metabolism, insulin secretion, and cancer-associated metabolic reprogramming[11].

References:

SIRT4 Related Products (1):

Cat. No. Product Name Effect Purity
  • HY-163316
    SIRT4-IN-1
    Inhibitor 99.94%
    SIRT4-IN-1 is a selective and potent Sirtuin 4 (Sirt4) inhibitor with an IC50 of 16 μM for hSirt4. SIRT4-IN-1 also inhibits hSirt1, hSirt2, hSirt3, hSirt4 and hSirt6. SIRT4-IN-1 competes with acyl peptide substrate for Sirt4's acyl binding site, and is noncompetitive with NAD+. SIRT4-IN-1 increases glutamate dehydrogenase (GDH) activity and rescues pyruvate dehydrogenase (PDH) activity. SIRT4-IN-1 inhibits adipocyte differentiation and suppresses Sirt4 overexpression-induced increased differentiation. SIRT4-IN-1 can be used for the researches of cancer and metabolic disease.